Literature DB >> 24080684

PARP inhibitors bounce back.

Ken Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24080684     DOI： 10.1038/nrd4147

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Authors:  Karen A Gelmon; Marc Tischkowitz; Helen Mackay; Kenneth Swenerton; André Robidoux; Katia Tonkin; Hal Hirte; David Huntsman; Mark Clemons; Blake Gilks; Rinat Yerushalmi; Euan Macpherson; James Carmichael; Amit Oza
Journal:  Lancet Oncol       Date:  2011-08-19       Impact factor: 41.316
  1 in total
  17 in total

1.  Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.

Authors:  Annika Kötter; Kerstin Cornils; Kerstin Borgmann; Jochen Dahm-Daphi; Cordula Petersen; Ekkehard Dikomey; Wael Y Mansour
Journal:  Mol Oncol       Date:  2014-07-01       Impact factor: 6.603

2.  Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.

Authors:  Albert A Antolín; Jordi Mestres
Journal:  Oncotarget       Date:  2014-05-30

3.  Proteomics approaches to identify mono-(ADP-ribosyl)ated and poly(ADP-ribosyl)ated proteins.

Authors:  Christina A Vivelo; Anthony K L Leung
Journal:  Proteomics       Date:  2014-12-15       Impact factor: 3.984

4.  PARP inhibitors and IR join forces to strike glioblastoma-initiating cells.

Authors:  N Lugli; I Kamileri; T D Halazonetis
Journal:  Cell Death Differ       Date:  2014-02       Impact factor: 15.828

5.  Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage.

Authors:  Xiangduo Kong; Gladys M S Cruz; Bárbara A Silva; Nicole M Wakida; Nima Khatibzadeh; Michael W Berns; Kyoko Yokomori
Journal:  J Vis Exp       Date:  2018-01-31       Impact factor: 1.355

6.  Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.

Authors:  Francesca Cottini; Teru Hideshima; Rikio Suzuki; Yu-Tzu Tai; Giampaolo Bianchini; Paul G Richardson; Kenneth C Anderson; Giovanni Tonon
Journal:  Cancer Discov       Date:  2015-06-16       Impact factor: 39.397

7.  Salvage of nicotinamide adenine dinucleotide plays a critical role in the bioenergetic recovery of post-hypoxic cardiomyocytes.

Authors:  Domokos Gero; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2015-10-14       Impact factor: 8.739

8.  Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.

Authors:  Yang Sun; Dana Gallacchi; Erik Y Zhang; Samuel B Reynolds; Lauren Robinson; Izabela A Malinowska; Terry T Chiou; Ana M Pereira; Chenggang Li; David J Kwiatkowski; Po-Shun Lee; Jane J Yu
Journal:  Am J Respir Cell Mol Biol       Date:  2014-12       Impact factor: 6.914

Review 9.  Therapeutic strategies for targeting the ovarian tumor stroma.

Authors:  Song Yi Ko; Honami Naora
Journal:  World J Clin Cases       Date:  2014-06-16       Impact factor: 1.337

10.  Basal activity of a PARP1-NuA4 complex varies dramatically across cancer cell lines.

Authors:  Kristin A Krukenberg; Ruomu Jiang; Judith A Steen; Timothy J Mitchison
Journal:  Cell Rep       Date:  2014-09-04       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.